Skip to Content
Search Menu

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

Adding polatuzumab vedotin, an antibody drug, to a treatment regimen together with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) significantly affects progression-free survival in patients with previously untreated diffuse large B-Cell lymphoma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Paul G. Richardson
ASH21Myeloma Play the Video 7:14
Andrew H. Wei

Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival

/ Andrew Wei
AMLASH21 Play the Video 8:47
Alexander Fosså

Perspective on the future standard of care for second-line treatment for patients with R/R LBCL

/ Alexander Fosså
ASH21Lymphoma Play the Video 4:46
Bjørn Tore Gjertsen

Relapse vaccine is a promising treatment for patients with AML

/ Bjørn Tore Gjertsen
AMLASH21 Play the Video 5:14
Manali Kamdar

CAR T Cell Therapy – a new standard of care for 2L treatment of R/R in Large B-cell Lymfoma

/ Manali Kamdar
ASH21Lymphoma Play the Video 5:52
Matthew S. Davids

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Matthew S. Davids
ASH21CLL Play the Video 2:37
Paolo Ghia

How can we use Minimal Residual Disease in the treatment of CLL?

/ Paolo Ghia
ASH21CLL Play the Video 2:03
Fredrik Schjesvold

The use of FDG PET/CT positivity as an indication for consolidation in myeloma patients after ASCT

/ Fredrik Schjesvold
ASH21Myeloma Play the Video 2:21
Frederick L. Locke

Real-world outcomes of axi-cel treatment of large B-cell lymphoma

/ Frederick L. Locke
ASH21 Play the Video 3:15
Back to top